The gene for Ran GTPase activating protein 1 (RANGAP1) is located on the human chromosome 22q13.2.
Specificity
Anti-phospho-RanGAP1 (pSer428) specifically recognizes human phospho-RanGAP1 (pSer428) (not yet tested in other species).
Application
Anti-phospho-RanGAP1 (pSer428) antibody produced in rabbit has been used in western blotting.
Biochem/physiol Actions
However, the SUMO-1 modification induces the interaction of RanGAP1 with the interphase nuclear pore complex (NPC) through binding to the nucleoporin Ras-related nuclear protein 1 binding protein 2 (RANBP2) and to Ubc9. RanGAP1 is phosphorylated on residues Thr409, Ser442 and Ser428. Phosphorylated RanGAP1 may aid the translocation of specific SUMO target proteins to RanBP2′s catalytic domain.
Ran GTPase Activating Protein 1 (RanGAP1) is a key regulator of Ran activity, by specifically inducing its GTPase activity. RanGAP1 is conjugated to the small ubiquitin-related modifier protein (SUMO-1). The activity of RanGAP1 is not substantially altered by SUMO-1 modification. Phosphorylation ensues before the breakdown of the nuclear envelope and is sustained during the entire mitosis process.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Storage and Stability
For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
RanGAP1 is the activating protein for the Ran GTPase. Vertebrate RanGAP1 is conjugated to a small ubiquitin-like protein, SUMO-1. This modification promotes association of RanGAP1 with the interphase nuclear pore complex (NPC) through binding to the nucleoporin RanBP2, also known
Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex
Reverter D and Lima CD
Nature, 435(7042), 687-687 (2005)
ON 01910. Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex
The majority of variants identified by genome-wide association studies (GWAS) reside in the noncoding genome, affecting regulatory elements including transcriptional enhancers. However, characterizing their effects requires the integration of GWAS results with context-specific regulatory activity and linkage disequilibrium annotations to
Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
